The Experts below are selected from a list of 507 Experts worldwide ranked by ideXlab platform

John H. Kempen - One of the best experts on this subject based on the ideXlab platform.

John D. Sheppard - One of the best experts on this subject based on the ideXlab platform.

Hidetoshi Yamashita - One of the best experts on this subject based on the ideXlab platform.

  • Difluprednate ophthalmic emulsion 0.05% as adjunctive treatment to panretinal photocoagulation for proliferative diabetic retinopathy with clinically significant macular edema.
    Retinal cases & brief reports, 2012
    Co-Authors: Teiko Yamamoto, Sakiko Goto, Sachi Abe, Eriko Kirii, Hidetoshi Yamashita
    Abstract:

    PURPOSE The purpose of this study was to evaluate the efficacy of topical Difluprednate ophthalmic emulsion in controlling progressive diabetic macular edema after panretinal photocoagulation. METHODS This was a case report of two patients with proliferative diabetic retinopathy combined with diabetic macular edema who underwent panretinal photocoagulation combined with use of a topical Difluprednate ophthalmic emulsion. RESULTS In the Case 1, retinal thickness was decreased 29% 1 month after the start of Difluprednate treatment and best-corrected visual acuity was improved 20/40 to 20/25. In Case 2, retinal thickness was decreased 43% after 1 month, and best-corrected visual acuity was improved 20/100 to 20/60 after 3 months. During the follow-up period, elevation of intraocular pressure, ocular infection, and progression of cataract were not detected, though superficial punctuate keratitis was observed in one case. CONCLUSION Topical Difluprednate ophthalmic emulsion was one of the possible choices to treat progressive diabetic macular edema after panretinal photocoagulation. It is mandatory to evaluate the effects and safety in further studies including many cases.

  • Difluprednate ophthalmic emulsion 0 05 as adjunctive treatment to panretinal photocoagulation for proliferative diabetic retinopathy with clinically significant macular edema
    Retinal Cases & Brief Reports, 2012
    Co-Authors: Teiko Yamamoto, Sakiko Goto, Sachi Abe, Eriko Kirii, Hidetoshi Yamashita
    Abstract:

    PURPOSE The purpose of this study was to evaluate the efficacy of topical Difluprednate ophthalmic emulsion in controlling progressive diabetic macular edema after panretinal photocoagulation. METHODS This was a case report of two patients with proliferative diabetic retinopathy combined with diabetic macular edema who underwent panretinal photocoagulation combined with use of a topical Difluprednate ophthalmic emulsion. RESULTS In the Case 1, retinal thickness was decreased 29% 1 month after the start of Difluprednate treatment and best-corrected visual acuity was improved 20/40 to 20/25. In Case 2, retinal thickness was decreased 43% after 1 month, and best-corrected visual acuity was improved 20/100 to 20/60 after 3 months. During the follow-up period, elevation of intraocular pressure, ocular infection, and progression of cataract were not detected, though superficial punctuate keratitis was observed in one case. CONCLUSION Topical Difluprednate ophthalmic emulsion was one of the possible choices to treat progressive diabetic macular edema after panretinal photocoagulation. It is mandatory to evaluate the effects and safety in further studies including many cases.

  • Treatment of diffuse diabetic macular oedema using steroid eye drops.
    Acta ophthalmologica, 2011
    Co-Authors: Sakiko Goto, Teiko Yamamoto, Sachi Abe, Eriko Kirii, Hidetoshi Yamashita
    Abstract:

    . Purpose:  To evaluate the efficacy of treatment of diffuse diabetic macular oedema (DME) with Difluprednate ophthalmic emulsion 0.05% (Durezol™) in eyes before vitrectomy. Methods:  This study enrolled patients with diffuse DME for whom more than 3 months had passed since prior treatment. Nineteen eyes in 15 subjects were treated with Difluprednate ophthalmic emulsion 0.05% four times daily for the first month and then twice daily for 2 months (treatment group). As a control group, 22 eyes in 11 subjects with DME were selected from subjects who underwent the steroid responder test. Results:  In the treatment group, the mean visual acuity (VA) (±SD) was 0.38 ± 0.25 logMAR and mean retinal thickness was 461.1 ± 109.9 μm at baseline. After 1 month of treatment, the mean VA had improved to 0.29 ± 0.25 (Wilcoxon rank-sum test, p = 0.30), while mean retinal thickness had decreased to 372.1 ± 70.0 μm (p = 0.006). The rate of effective improvement in retinal thickness was 42% and that of VA was 26%. In the control group, changes in neither VA nor retinal thickness were significant. Conclusions:  Eye drop therapy using Difluprednate ophthalmic emulsion 0.05% is a useful and effective treatment modality without surgical intervention or severe side-effects.

  • Steroid eye drop treatment (Difluprednate ophthalmic emulsion) is effective in reducing refractory diabetic macular edema
    Graefe's Archive for Clinical and Experimental Ophthalmology, 2010
    Co-Authors: Sakiko Nakano, Teiko Yamamoto, Sachi Abe, Eriko Kirii, Hidetoshi Yamashita
    Abstract:

    Purpose To evaluate the efficacy of treatment of refractory diabetic macular edema (DME) after vitrectomy with Difluprednate ophthalmic emulsion 0.05% (Durezol^TM), and to compare this treatment with sub-Tenon’s injection of triamcinolone (STTA). Methods This study enrolled patients with refractory diabetic macular edema that persisted despite pars plana vitrectomy in our clinic. In all subjects, more than 3 months had passed since prior treatment. Eleven eyes in ten subjects were treated with STTA (STTA group), and 11 eyes in seven subjects were treated with Difluprednate ophthalmic emulsion 0.05% (Durezol^TM, Sirion Therapeutics Inc., USA) 4 times daily for the first month and then twice daily for 2 months (eye drop group). Results In the eye drop group, mean VA (± SD) was 0.67 ± 0.35 logMAR and mean retinal thickness was 500.6 ± 207.7 μm at baseline. After 3 months of treatment, mean VA was 0.67 ± 0.29 and mean retinal thickness had decreased to 341.2 ± 194.8 μm. The mean minimum value of RT during the treatment period was 300.6 ± 123.2 μm, and significantly lower than that at baseline (Mann–Whitney U test: P  = 0.003). In the STTA group, mean VA (± SD) was 0.67 ± 0.35 logMAR, and mean retinal thickness was 543.3 ± 132.6 μm at baseline. After 3 months of treatment, mean VA was 0.49 ± 0.67, and mean retinal thickness had decreased to 378.6 ± 135 μm. The mean minimum value of RT during the treatment period was 349.9 ± 113.8 μm, and significantly lower than at baseline (Mann–Whitney U test: P  = 0.003). The rate of effective improvement in RT did not differ between the eye drop group (73%) and STTA group (84%) (Fisher’s exact test: P  = 1). Conclusions Comparable improvements of retinal thickness were observed in the STTA and eye drop groups. Instillation of Difluprednate ophthalmic emulsion 0.05% is a safe and effective treatment that does not require surgical intervention and does not produce severe side-effects.

  • steroid eye drop treatment Difluprednate ophthalmic emulsion is effective in reducing refractory diabetic macular edema
    Graefes Archive for Clinical and Experimental Ophthalmology, 2010
    Co-Authors: Sakiko Nakano, Teiko Yamamoto, Eriko Kirii, Hidetoshi Yamashita
    Abstract:

    Purpose To evaluate the efficacy of treatment of refractory diabetic macular edema (DME) after vitrectomy with Difluprednate ophthalmic emulsion 0.05% (DurezolTM), and to compare this treatment with sub-Tenon’s injection of triamcinolone (STTA).

Melissa M. Toyos - One of the best experts on this subject based on the ideXlab platform.

José Bonilla-garcía - One of the best experts on this subject based on the ideXlab platform.

  • Bioavailability of generic 0.05% Difluprednate emulsion in the aqueous humor, cornea, and conjunctiva of New Zealand rabbits after a single dose compared with commercial Difluprednate
    Journal of Ophthalmic Inflammation and Infection, 2017
    Co-Authors: Arieh Mercado-sesma, Angélica Contreras-rubio, Leopoldo Baiza-durán, Oscar Olvera-montaño, Mónica Miranda-robles, José Bonilla-garcía
    Abstract:

    Background To determine the concentration after a single dose of generic 0.05% Difluprednate and commercial Difluprednate in the aqueous humor, cornea, and conjunctiva of New Zealand rabbits, a preclinical study in 72 male New Zealand white rabbits was performed. A single dose (50 μL) of two 0.05% Difluprednate ophthalmic formulations was instilled in both eyes. Conjunctiva, cornea, and aqueous humor samples were collected at nine time points over 8 h (four animals per time point). The active metabolite of Difluprednate, 17-difluoroprednisolone-butyrate (DFB), concentrations was quantified using HPLC. Results Measurable levels of DFB were quantified in all three ocular tissues. After a single instillation, the highest concentration of Difluprednate was found between 30 and 60 min in the conjunctiva, cornea, and aqueous humor, respectively. There was no significant difference between both formulations in any tissue at any time point. After 3 h, no metabolites of either emulsion were found in any tissue. Conclusions Difluprednate penetrates into different ocular tissues. Generic Difluprednate has a similar pharmacokinetic profile compared with commercial Difluprednate.

  • Bioavailability of generic 0.05% Difluprednate emulsion in the aqueous humor, cornea, and conjunctiva of New Zealand rabbits after a single dose compared with commercial Difluprednate
    Journal of ophthalmic inflammation and infection, 2017
    Co-Authors: Arieh Mercado-sesma, Angélica Contreras-rubio, Leopoldo Baiza-durán, Oscar Olvera-montaño, Mónica Miranda-robles, José Bonilla-garcía
    Abstract:

    To determine the concentration after a single dose of generic 0.05% Difluprednate and commercial Difluprednate in the aqueous humor, cornea, and conjunctiva of New Zealand rabbits, a preclinical study in 72 male New Zealand white rabbits was performed. A single dose (50 μL) of two 0.05% Difluprednate ophthalmic formulations was instilled in both eyes. Conjunctiva, cornea, and aqueous humor samples were collected at nine time points over 8 h (four animals per time point). The active metabolite of Difluprednate, 17-difluoroprednisolone-butyrate (DFB), concentrations was quantified using HPLC. Measurable levels of DFB were quantified in all three ocular tissues. After a single instillation, the highest concentration of Difluprednate was found between 30 and 60 min in the conjunctiva, cornea, and aqueous humor, respectively. There was no significant difference between both formulations in any tissue at any time point. After 3 h, no metabolites of either emulsion were found in any tissue. Difluprednate penetrates into different ocular tissues. Generic Difluprednate has a similar pharmacokinetic profile compared with commercial Difluprednate.